Patents by Inventor Jean-Pierre Salles
Jean-Pierre Salles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230293636Abstract: The present invention relates to an anti-IL-6 agent for use in a method of preventing or treating post-operative pain in an individual.Type: ApplicationFiled: December 31, 2020Publication date: September 21, 2023Inventors: Rene AZOULAI, Xavier CASSARD, Jean-Pierre SALLES, Jean-Francois ZAGURY
-
Patent number: 11717466Abstract: A sexual toy is provided that is made from a composite material formed from joining, at least, two components, where a first component is an elastomer, and a second component is a granulated element. The sexual toy can include a sheath of silicone and a rigid core.Type: GrantFiled: August 14, 2018Date of Patent: August 8, 2023Assignee: CNEX ASESORAMIENTO PARA LA IMPORTACIÓN, S.L.Inventor: Olivier Jean-Pierre Salle Phelippes De La Marnierre
-
Publication number: 20230131650Abstract: The present invention relates to an immunogenic conjugate comprising: a carrier protein and at least one polypeptide having at most 100 amino acids comprising a sequence of 5 to 50 amino acids of interleukin 6 (IL-6) or IL-6 receptor (IL-6R), or a variant sequence having at least 75% identity with the sequence of 5 to 50 amino acids of IL-6 or IL-6R, wherein the polypeptide is covalently linked to the carrier protein and the carrier protein is a non-toxic mutant diphtheria toxin.Type: ApplicationFiled: December 31, 2020Publication date: April 27, 2023Inventors: Lucille DESALLAIS, Jean-Pierre SALLES, Jean-Francois ZAGURY
-
Publication number: 20210395368Abstract: The present invention relates to a polypeptide which comprises or consists of—a first sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 55 to 67 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a second sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 85 to 101 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a third sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 111 to 127 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a fourth sequence consisting of at least 8 contiguous amino acid resiType: ApplicationFiled: March 5, 2019Publication date: December 23, 2021Applicants: Peptinov SAS, Conservatoire National des Arts et MetiersInventors: Lucille DESALLAIS, Jean-Pierre SALLES, Jean-Fran9ois ZAGURY
-
Publication number: 20210371496Abstract: The present invention relates to a polypeptide which comprises or consists of:—a first sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 123 to 137 of the PD-1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-1 protein; and/or—a second sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 66 to 81 of the PD-1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-1 protein; and/or—a third sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 95 to 110 of the PD-1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-1 protein; and/or—a fourth sequence consisting of at least 8 contiguous amino acid residuesType: ApplicationFiled: March 5, 2019Publication date: December 2, 2021Inventors: Lucille DESALLAIS, Jean-Pierre SALLES, Jean-François ZAGURY
-
Publication number: 20200246215Abstract: A sexual toy is provided that is made from a composite material formed from joining, at least, two components, where a first component is an elastomer, and a second component is a granulated element. The sexual toy can include a sheath of silicone and a rigid core.Type: ApplicationFiled: August 14, 2018Publication date: August 6, 2020Applicant: CNEX ASESORAMIENTO PARA LA IMPORTACIÓN, S.L.Inventor: Olivier Jean-Pierre Salle Phelippes De La Marnierre
-
Patent number: 8173843Abstract: Compounds derived from ?-C-phenyl-N-tert-butylnitrone, a process for the preparation thereof and use thereof for the preparation of medicaments for use in preventing or treating oxidative stress-related diseases.Type: GrantFiled: March 15, 2007Date of Patent: May 8, 2012Assignees: TS Pharma, Universite d'Avignon Et des Pays du VaucluseInventors: Grégory Durand, Ange Polidori, Bernard Pucci, Jean-Pierre Salles
-
Publication number: 20090306001Abstract: Compounds derived from ?-C-phenyl-N-tert-butylnitrone, a process for the preparation thereof and use thereof for the preparation of medicaments for use in preventing or treating oxidative stress-related diseases.Type: ApplicationFiled: March 15, 2007Publication date: December 10, 2009Applicants: TS PHARMA, UNIVERSITE D'AVIGNON ET DESPAYS DU VAUCLUSEInventors: Grégory Durand, Ange Polidori, Bernard Pucci, Jean-Pierre Salles
-
Publication number: 20070275046Abstract: The invention relates to novel surfactant compounds and the use thereof for preparing metastable supramolecular systems or nanoparticles. Said nanoparticles may be used as vectors for active ingredients, in particular therapeutic active ingredients.Type: ApplicationFiled: October 19, 2004Publication date: November 29, 2007Applicants: TS PHARMA, UNIVERSITE D'AVIGNON ET DES PAYS DU VAUCLUSEInventors: Bernard Pucci, Ange Polidori, Nicolas Michel, Anne-Sylvie Fabiano, Christiane Contino-Pepin, Jean-Pierre Salles
-
Patent number: 6656497Abstract: The invention concerns liposome vectors, in powder form, of active principles, and more particularly active principles sensitive to digestive and/or plasmatic degradation, such as proteins, and their application as medicine. Said liposome vectors of active principles consist of a powder composition essentially constituted of unilamellar liposomes comprising an external lipid phase consisting of class 4 lipids (phospholipids), optionally associated with class 2 substances, class 3 substances and/or class 5 substances and an internal aqueous nucleus consisting of a mixture M of at least two different non-polymerisable gelling agents (G1 and G2) whereof the gel-sol phase transition is not less than 37° C.Type: GrantFiled: February 17, 2000Date of Patent: December 2, 2003Assignee: LipogelInventor: Jean-Pierre Salles
-
Publication number: 20020146447Abstract: The invention concerns liposome vectors, in powder form, of active principles, and more particularly active principles sensitive to digestive and/or plasmatic degradation, such as proteins, and their application as medicine. Said liposome vectors of active principles consist of a powder composition essentially constituted of unilamellar liposomes comprising an external lipid phase consisting of class 4 lipids (phospholipids), optionally associated with class 2 substances, class 3 substances and/or class 5 substances and an internal aqueous nucleus consisting of a mixture M of at least two different non-polymerisable gelling agents (G1 and G2) whereof the gel-sol phase transition is not less than 37° C.Type: ApplicationFiled: February 17, 2000Publication date: October 10, 2002Inventor: JEAN-PIERRE SALLES
-
Patent number: 6331315Abstract: The invention concerns powder compositions of stabilised unilamellar liposomes, comprising at least an external lipid phase and a internal aqueous polar nucleus gelled at room temperature, the method for preparing them and their applications as nutritional additives and in pharmaceutical compositions to be orally administered (with action against lipemia). Said compositions essentially consist of unilamellar liposomes comprising an external lipid phase consisting of class 4 lipids (phospholipids) and an internal aqueous nucleus consisting essentially of a mixture M of at least two different non-polymerisable gelling agents (G1 and G2) whereof the gel-sol phase transition point is not less than 37° C.Type: GrantFiled: February 16, 2000Date of Patent: December 18, 2001Assignee: LipogelInventor: Jean-Pierre Salles
-
Patent number: 6221387Abstract: Microspheres comprising a gelified polar core which is optionally surrounded by concentric and alternating superimposed n lipidic bilayers or n aqueous liquid layers and n gelified polar layers, n being an integer. The microspheres of the invention are obtainable by delipidation of liposomes designated as liposomes having a gelified polar core, of the type comprising at least one outer lipidic bilayer and at least one inner polar aqueous phase containing a gelified substance.Type: GrantFiled: April 28, 1999Date of Patent: April 24, 2001Assignee: LipogelInventors: Jacques Hauton, Jean-Pierre Salles
-
Patent number: 5945120Abstract: Microspheres comprising a gelified polar core which is optionally surrounded by concentric and alternating superimposed n lipidic bilayers or n aqueous liquid layers and n gelified polar layers, n being an integer. The microspheres of the invention are obtainable by delipidation of liposomes designated as liposomes having a gelified polar core, of the type comprising at least one outer lipidic bilayer and at least one inner polar aqueous phase containing a gelified substance.Type: GrantFiled: December 13, 1996Date of Patent: August 31, 1999Assignee: LipogelInventors: Jacques Hauton, deceased, Jean-Pierre Salles